MAP2K7 and colonic neoplasm: Finally, accordingly to what we previously reported for colon cancer cells [18] we confirmed that p65BTK expression is regulated by the activation of the RAS/MAPK pathway by showing that its expression, as well as its activation, is down-regulated upon the treatment of NSCLC cells with Trametinib, a MEK inhibitor (Fig. 2d).